The company said, “Taking into account the $15.3 million we raised in 2023, we have the resources to deliver two sets of preclinical data and three sets of clinical data in 2024. Our development pipeline now includes five programs, of which four are at clinical stage. With the pipeline stronger than it has ever been, we are enthusiastic about the potential for our Company in 2024 and beyond.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa says early trials of MTX110 show promise in extending life expectancy
- Biodexa Pharmaceuticals files to sell 1.28B ordinary shares for holders
- Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
- Biodexa announces results for Phase 1 study of MTX110, update for Tolimidone
